Investor's Business Daily on MSN
Vertex Pharma makes a $10 billion deal; Crinetics stock doubles
Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.
Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix ...
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...
The Europe transgenic animal model market is set for robust growth, driven by surging biotechnology investments, demand for ...
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
Riverside Homestead on MSNOpinion
A California wildfire hit 0% containment - then the forecast map already had the West marked, "Where the West might burn"
The strongest political angle is that ordinary people are being asked to absorb the cost and risk of systems they did not ...
Funds will be crucial to accelerate Florida citrus recovery in the face of citrus greening, hurricanes and extreme weather ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Researchers have uncovered an unexpected antiviral defense system in sea anemones that works nothing like the one humans rely ...
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results